A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra™): Immunogenicity and safety profile

Hanna Czajka; Volker Schuster; Fred Zepp; Susanna Esposito; Martine Douha; Paul Willems

doi:10.1016/j.vaccine.2009.07.076

A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra™): Immunogenicity and safety profile

Hanna Czajka, Volker Schuster, Fred Zepp, Susanna Esposito, Martine Douha, Paul Willems

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Priorix-Tetra™ (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR (Priorix™) and varicella (Varilrix™) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into routine vaccination programmes.

Original language	English
Pages (from-to)	6504-6511
Number of pages	8
Journal	Vaccine
Volume	27
Issue number	47
DOIs	https://doi.org/10.1016/j.vaccine.2009.07.076
Publication status	Published - Nov 5 2009

Keywords

Combined MMRV vaccine
Immunogenicity
Reactogenicity

ASJC Scopus subject areas

Immunology and Microbiology(all)
Infectious Diseases
Public Health, Environmental and Occupational Health
veterinary(all)
Molecular Medicine

Access to Document

10.1016/j.vaccine.2009.07.076

Cite this

@article{865a70085bfe4c2fa5df296022bf65ee,

title = "A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra{\texttrademark}): Immunogenicity and safety profile",

abstract = "Priorix-Tetra{\texttrademark} (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR (Priorix{\texttrademark}) and varicella (Varilrix{\texttrademark}) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into routine vaccination programmes.",

keywords = "Combined MMRV vaccine, Immunogenicity, Reactogenicity",

author = "Hanna Czajka and Volker Schuster and Fred Zepp and Susanna Esposito and Martine Douha and Paul Willems",

year = "2009",

month = nov,

day = "5",

doi = "10.1016/j.vaccine.2009.07.076",

language = "English",

volume = "27",

pages = "6504--6511",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "47",

}

TY - JOUR

T1 - A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra™)

T2 - Immunogenicity and safety profile

AU - Czajka, Hanna

AU - Schuster, Volker

AU - Zepp, Fred

AU - Esposito, Susanna

AU - Douha, Martine

AU - Willems, Paul

PY - 2009/11/5

Y1 - 2009/11/5

N2 - Priorix-Tetra™ (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR (Priorix™) and varicella (Varilrix™) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into routine vaccination programmes.

AB - Priorix-Tetra™ (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR (Priorix™) and varicella (Varilrix™) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into routine vaccination programmes.

KW - Combined MMRV vaccine

KW - Immunogenicity

KW - Reactogenicity

UR - http://www.scopus.com/inward/record.url?scp=70350786912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350786912&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.07.076

DO - 10.1016/j.vaccine.2009.07.076

M3 - Article

C2 - 19665608

AN - SCOPUS:70350786912

SN - 0264-410X

VL - 27

SP - 6504

EP - 6511

JO - Vaccine

JF - Vaccine

IS - 47

ER -

A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra™): Immunogenicity and safety profile

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this